Emergent Biosolutions Inc (NYSE: EBS), a maker of vaccines and products for infectious diseases as well as chemical, biological or nuclear attacks, picked up a sell-side bull Wednesday.
Argus analyst Mike Jaffe initiated coverage of Emergent BioSolutions with a Buy and $62 price target.
With the only FDA-approved anthrax vaccine, BioThrax, Emergent BioSolutions is on track to report solid earnings growth over the next several years, particularly due to strong demand from the U.S. military, Jaffe said in the initiation note.
Argus projects that Emergent BioSolutions will benefit from recently acquired products such as the ACAM2000 for smallpox, as well as from its new product pipeline and strong cost controls.
The company, which is heavily reliant on the government for much of its revenue, has begun to diversify by developing new products for both government as well as non-government customers and through international expansion, Jaffe said.
The discounted valuation at which the company's shares trade is warranted, given its overreliance on the U.S. government, the analyst said. That said, the current discount is too deep given expectations for 24-percent earnings growth over the next five years versus 15-percent growth among peers, according to Argus.
The Price Action
Emergent BioSolutions shares have added about 16 percent year-to-date.
At the time of publication, the stock was rallying 1.47 percent to $54.53.
4 Biotech Stocks To Better Your Financial Health This Winter
Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111
Latest Ratings for EBS
|Jun 2018||Argus||Initiates Coverage On||Buy|
|Jun 2018||Cantor Fitzgerald||Initiates Coverage On||Overweight|
|Apr 2018||Wells Fargo||Downgrades||Outperform||Market Perform|
View More Analyst Ratings for EBS
View the Latest Analyst Ratings
See more from Benzinga
- After A Mixed Q1 Print, Drexel Hamilton Says SAIC Shares Are Fairly Valued
- MGIC Downgraded As Shares Close In On BofA's Price Target
- Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.